Approved HER2 inhibitors include neratinib, tucatinib, afatinib, pertuzumab, and trastuzumab, which target the overexpression of HER2 receptors in NSCLC, breast cancer, and gastric cancer [139]. The gene discussed is ERBB2; the disease is breast carcinoma.